Novartis Message Board - Msg: 13033033

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 123.79

+1.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (265)	3/3/2000 8:20:00 AM
From: Jack Hartmann	Read Replies (1) of 296

Organogenesis: Apligraf US Sales In Feb. Reach 810 March 2, 2000 Dow Jones Newswires CANTON, Mass. -- Organogenesis Inc. (ORG) said U.S. commercial sales of the Apligraf reached 810 units during February. In a press release Thursday, the company said Novartis AG (Z.NOV) markets Apligraf, which is used to treat venous leg ulcers. In December, Organogenesis applied to the Food and Drug Administration for approval to market the Apligraf skin construct to treat diabetic foot ulcers. Organogenesis develops and makes medical products containing living cells or natural connective tissue. -Freddy Sebastian; Dow Jones Newswires; 201-938-5400 I bought in this week at $64+. waiting for listing to NYSE in May. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next